Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]. (August 2017) - Swords, Ronan T.; Greenberg, Peter L.; Wei, Andrew H.; Durrant, Simon; Advani, Anjali S.; Hertzberg, Mark S.; Lewis, Ian D.; Rivera, Gabriel; Gratzinger, Dita; Fan, Alice C.; Felsher, Dean W.; Cortes, Jorge E.; et al.